Eric Antwi-Donkor, MD
Nephrology · Washington, DCNPI 1629053848
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (47.1%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Medtronic at 30.7% of the total. 2025 is the largest year on record at $617, 4.1 times the $149 reported in 2019.
Across 44 payments — averaging $45.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$616
- Vifor Pharma, Inc.$384
- Amgen$299
- Travere Therapeutics, Inc.$226
- Aurinia Pharma U.S., Inc.$113
- Baxter Healthcare$66
- plus $301 from 9 others
What the payments were for
- Consulting fees$22511%
- Speaking & faculty fees$20010%
- Travel & lodging$61631%
- Food & beverage$94447%
- Education$201%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 2 | $616 |
| Vifor Pharma, Inc. | 6 | $384 |
| Amgen | 10 | $299 |
| Travere Therapeutics, Inc. | 3 | $226 |
| Aurinia Pharma U.S., Inc. | 6 | $113 |
| Baxter Healthcare | 1 | $66 |
| Novartis | 3 | $61 |
| Ardelyx, Inc. | 3 | $52 |
| Mallinckrodt Enterprises LLC | 2 | $52 |
| Bayer | 2 | $39 |
| AstraZeneca | 2 | $39 |
| GSK | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Fresenius USA Marketing, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYMPLICITY G3$616
- Veltassa$200
How this compares
$2,005 in reported general payments places this provider in the 65th percentile of 62 nephrology providers in District of Columbia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sevelamer Carbonate | 36 | $14,068 |
| Calcitriol | 11 | $336 |
| Carvedilol | 33 | $295 |
| Amlodipine Besylate | 28 | $197 |
| Famotidine | 15 | $191 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 19 | $168 |
| Losartan Potassium | 14 | $120 |
| Furosemide | 15 | $107 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Washington
- Ashte CollinsWashington$1M
- Bruce LeslieWashington$217K
- Janani RangaswamiWashington$152K
- Robert RubinWashington$119K
- Ehsan Nobakht HaghighiWashington$50K
- Christopher WilcoxWashington$41K
- Michael LipkowitzWashington$21K
- Dominic RajWashington$19K
- Cosette JamiesonWashington$13K
- Elwin BustosWashington$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.